ORAGENICS INC (OGEN) Fundamental Analysis & Valuation

NYSEARCA:OGEN • US6840236094

Current stock price

0.6009 USD
+0.04 (+6.86%)
Last:

This OGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. OGEN Profitability Analysis

1.1 Basic Checks

  • OGEN had negative earnings in the past year.
  • In the past year OGEN has reported a negative cash flow from operations.
  • OGEN had negative earnings in each of the past 5 years.
  • OGEN had a negative operating cash flow in each of the past 5 years.
OGEN Yearly Net Income VS EBIT VS OCF VS FCFOGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -83.18%, OGEN is doing worse than 69.44% of the companies in the same industry.
  • OGEN has a Return On Equity (-107.49%) which is in line with its industry peers.
Industry RankSector Rank
ROA -83.18%
ROE -107.49%
ROIC N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OGEN Yearly ROA, ROE, ROICOGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K 4K -4K -6K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for OGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OGEN Yearly Profit, Operating, Gross MarginsOGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. OGEN Health Analysis

2.1 Basic Checks

  • OGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, OGEN has more shares outstanding
  • Compared to 5 years ago, OGEN has more shares outstanding
  • OGEN has a worse debt/assets ratio than last year.
OGEN Yearly Shares OutstandingOGEN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
OGEN Yearly Total Debt VS Total AssetsOGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • Based on the Altman-Z score of -26.04, we must say that OGEN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of OGEN (-26.04) is worse than 87.04% of its industry peers.
  • OGEN has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of OGEN (0.04) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -26.04
ROIC/WACCN/A
WACC8.73%
OGEN Yearly LT Debt VS Equity VS FCFOGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • OGEN has a Current Ratio of 4.42. This indicates that OGEN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of OGEN (4.42) is comparable to the rest of the industry.
  • OGEN has a Quick Ratio of 4.42. This indicates that OGEN is financially healthy and has no problem in meeting its short term obligations.
  • OGEN has a Quick ratio (4.42) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.42
Quick Ratio 4.42
OGEN Yearly Current Assets VS Current LiabilitesOGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. OGEN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 82.62% over the past year.
  • Looking at the last year, OGEN shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)82.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.64%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 15.02% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OGEN Yearly Revenue VS EstimatesOGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2028 500K 1M 1.5M 2M
OGEN Yearly EPS VS EstimatesOGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -200 -400 -600 -800 -1K

More info and screens

Find the best growth stocksShow best growing peers

1

4. OGEN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for OGEN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OGEN Price Earnings VS Forward Price EarningsOGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OGEN Per share dataOGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as OGEN's earnings are expected to grow with 25.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y25.6%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OGEN Dividend Analysis

5.1 Amount

  • OGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OGEN Fundamentals: All Metrics, Ratios and Statistics

ORAGENICS INC

NYSEARCA:OGEN (4/6/2026, 12:47:47 PM)

0.6009

+0.04 (+6.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners7.03%
Inst Owner Change0%
Ins Owners0.4%
Ins Owner Change-0.03%
Market Cap2.51M
Revenue(TTM)N/A
Net Income(TTM)-10.57M
Analysts82.86
Price Target2.04 (239.49%)
Short Float %19.48%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.25
P/tB 0.25
EV/EBITDA N/A
EPS(TTM)-47.88
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0
BVpS2.36
TBVpS2.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.18%
ROE -107.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-410.14%
ROA(5y)-285.51%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.42
Quick Ratio 4.42
Altman-Z -26.04
F-Score6
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.64%
EPS Next Y96.67%
EPS Next 2Y40.35%
EPS Next 3Y25.6%
EPS Next 5Y15.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y49.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.76%
EBIT Next 3Y-28.26%
EBIT Next 5YN/A
FCF growth 1Y2.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.21%
OCF growth 3YN/A
OCF growth 5YN/A

ORAGENICS INC / OGEN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ORAGENICS INC (OGEN) stock?

ChartMill assigns a fundamental rating of 1 / 10 to OGEN.


What is the valuation status of ORAGENICS INC (OGEN) stock?

ChartMill assigns a valuation rating of 1 / 10 to ORAGENICS INC (OGEN). This can be considered as Overvalued.


How profitable is ORAGENICS INC (OGEN) stock?

ORAGENICS INC (OGEN) has a profitability rating of 0 / 10.


How financially healthy is ORAGENICS INC?

The financial health rating of ORAGENICS INC (OGEN) is 3 / 10.